Humana (HUM) is back in focus after its fourth quarter 2025 results and 2026 outlook pointed to lower expected profitability, with Medicare Advantage Star Ratings creating a sizeable earnings headwind despite higher revenue and membership.

The recent guidance cut and Stars headwind have gone hand in hand with a sharp reset in expectations, with a 30 day share price return of 32.84% decline and a 1 year total shareholder return of 26.46% decline pointing to fading momentum despite ongoing product launches, AI initiatives like Agent Assist with Google Cloud, and new partnerships such as the Zynex provider agreement and CenterWell’s MaxHealth acquisition.

If Humana’s volatility has you reassessing your watchlist, it could be worth scanning our screener of 25 healthcare AI stocks to see how other health related AI names are positioned right now.

With Humana shares down sharply over the past year and the stock trading at a discount to published analyst targets, the real question is whether this reset is overdone or whether the market is simply catching up to slower earnings growth.

Most Popular Narrative: 35.9% Undervalued

Humana’s most followed narrative puts fair value at $287.38 versus a last close of $184.10, framing the recent sell off as a sizable valuation gap to watch.

The progress in closing gaps in care and achieving high Stars ratings is targeted to deliver sustainable clinical outcomes and boost quality, contributing positively to future earnings and competitive stability.

Read the complete narrative. Read the complete narrative.

Want to see what is sitting underneath that fair value gap? Revenue growth assumptions, margin rebuild and future earnings power all sit at the core of this story. Curious which levers do the heavy lifting in the model, and how that ties back to today’s price?

Result: Fair Value of $287.38 (UNDERVALUED)

However, the picture could shift quickly if outcomes of Medicare Advantage Stars litigation or changes in ACA-related subsidies affect Humana’s revenue and margin assumptions more than expected.

Build Your Own Humana Narrative

If you look at this and feel differently, or simply want to test your own assumptions against the data, you can build a Humana view that fits your thesis in just a few minutes: Do it your way

A great starting point for your Humana research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If Humana is only one piece of your watchlist, now is a good moment to broaden your scope with a few focused stock ideas from our screener.

• Target potential mispricings by scanning our list of 53 high quality undervalued stocks that combine strong fundamentals with room for the market to catch up.
• Strengthen your income stream by reviewing 13 dividend fortresses that aim to pair higher yields with resilience across different conditions.
• Prioritize resilience first and filter out the noise using our 85 resilient stocks with low risk scores, so you do not overlook companies with steadier risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.